To transport, or not to transport, that is the axon.

Gorazd Bernard Stokin, Ph.D., MD

Research focus
The TAP team aims at furthering our understanding of aging and age-related disorders, in particular, neurodegenerative ones. TAP focuses on understanding the murky grey zone between physiological aging and preclinical and early symptomatic neurodegenerative disorders such as Alzheimer`s disease. Intriguingly, traumatic brain injury recapitulates many of the features found in aging and early symptoma­tic Alzheimer`s disease. Uniquely TAP takes advantage of its clinical, as well as basic, scientific knowledge and experience to bring further progress in its specific research field of interest. Thorough understanding of behavioral and cognitive neurology is coupled to stem cells and animal models of aging and neurode­generation, with particular attention to synaptic and axonal changes.

Research objectives
• Identification of the earliest change of aging and neurodegeneration.

• Understanding the mechanism underlying aging and neurodegeneration.

• Generation of human stem cells derived neuronal and glial lineages to address aging and neurodege­neration.

Main partners

• Mayo Clinic, Rochester, MN, USA

• University of California, San Diego, CA, USA

• University of Buenos Aires, Buenos Aires, Argentina

Offered services and expertise

• Behavioral and cognitive testing.

• Real time in vivo imaging.

• Production of human stem cells derived neuronal and glial lineages.

• Automated immunochemistry scoring.

Top publications

  • STOKIN, G.B., POPOVIĆ, M., GELPI, E., KOGOJ, A., DALMAU, J., GRAUS, F. Neuropathologicalfeaturesof anti-Dipeptidyl-Peptidase-LikeProtein-6 antibodyencephalitis. Neurology. 2015,84(4), 430-432.
  • MELLONE, M., KESTORAS, D., ANDREWS, M.R., DASSIE, E., CROWTHER, R.A., STOKIN, G.B., TINSLEY, J., HORNE, G., GOEDERT, M., TOLKOVSKY, A., SPILLANTINI, M.-G. Tau PathologyisPresentIn Vivoand DevelopsIn Vitro in Sensory NeuronsfromHuman P301S TauTransgenicMice A System forScreeningDrugsagainstTauopathies. Progressive tau pathology and axonopathyin vivoand in cultureofadult sensory neuronsexpressing P301S human tau. JournalofNeuroscience. 2013, 33(46), 18175-18189.
  • ZERR, I., KALLENBERG, K., SUMMERS, D.M., ROMERO, C., TARATUTO, A., HEINEMANN, U., BREITHAUPT, M., VARGES, D., MEISSNER, B., LADOGANA, A., SCHUUR, M., HAIK, S., COLLINS, S.J., JANSEN, G.H., STOKIN, G.B., PIMENTEL, J., HEWER, E., COLLIE, D., SMITH, P., ROBERTS, H., BRANDEL, J.P., VAN DUIJN, C., POCCHIARI, M., BEGUE, C., CRAS, P., WILL, R.G., SANCHEZ, JUAN P. UpdatedclinicaldiagnosticcriteriaforsporadicCreutzfeldt Jakob disease. Brain. 2009, 132(10), 2659-2668.
  • STOKIN, G. B. AND L. S. B. GOLDSTEIN. Axonal transport and Alzheimer’s disease. Annual Review of Biochemistry. 2006, 75, 607-627.
  • STOKIN, G. B., C. LILLO, T. L. FALZONE, R. G. BRUSCH, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science. 2005, 307(5713), 1282-1288.

Other selected results

  • Development of a transcriptome/proteome database to Alzheimer´s disease.
  • Generation of a novel method to development of human stem cells derived neuronal and glial lineages.
  • Designing innovative approaches to real time in vivo imaging.